Business · 21/05/2021
FDA Releases Draft Guidance on Adjusting for Covariates in Clinical Trials for Drugs and Biological Products
The Food and Drug Administration (FDA) has published a draft guidance outlining its recommendations for adjusting for covariates in randomized clinical trials for drugs and biologics, which is expected to be finalized and replace its previous 2019 guidance
Original source language: Federal Register — Food and Drug AdministrationOpen original release →